(Reuters) - Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...

The Carlyle Group offers solid investment-grade debt with consistent dividends. Learn why CG stock’s baby bond, CGABL, is a ...

Matt Savino, Carlyle global head of capital markets, expects the IPO market to improve in 2025. He is on "Bloomberg ." ...

BofA analyst Craig Siegenthaler lowered the firm’s price target on Carlyle (CG) to $47 from $50 and keeps an Underperform ...

The Carlyle Group Inc. (NASDAQ:CG), a global investment firm with a market capitalization of $18.52 billion, has recently ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

The Carlyle Group (NASDAQ:CG – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” ...

SOMERVILLE, Mass., February 21, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by global ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

Markets worldwide defied expectations in 2024 led by the dominating performance of mega-cap technology stocks known as the ...

Bank of America Securities analyst Craig Siegenthaler maintained a Sell rating on Carlyle Group (CG – Research Report) yesterday and set a ...